The current kevetrin trial is for ovarian cancer. We surmise that it was the one that was most evidently affected in the Phase 1 clinical trial, so they are focusing on it as proof of concept. Cancer trials can be horrendously complex and expensive so this is a smart move to get proof of concept with a cancer that seemed to respond well. That makes it easier to get a deep-pockets partner so they can go full steam ahead after this trial.